Personalis Gets Medicare Coverage for Genomic Tumor Profiling Assay
The assay received a final Medicare coverage determination, providing access for Medicare and Medicare Advantage beneficiaries.
Read MorePosted by Andy Lundin | Jan 16, 2024 | Molecular Diagnostics |
The assay received a final Medicare coverage determination, providing access for Medicare and Medicare Advantage beneficiaries.
Read MorePosted by Andy Lundin | Jan 16, 2024 | Lung Cancer |
The epigenomic technology platform predicts and monitors immunotherapy responses for patients with non-small cell lung cancer (NSCLC).
Read MorePosted by Andy Lundin | Jan 9, 2024 | Cancer, Research |
PanGIA Biotech is preparing to launch new clinical studies in multi-cancer early detection using the PanGIA Liquid Biopsy Platform.
Read MorePosted by Andy Lundin | Jan 8, 2024 | Lung Cancer |
ChromaCode will collaborate with Tennessee Oncology to test the performance of ChromaCode’s HDPCR NSCLC biomarker assay.
Read MorePosted by Andy Lundin | Jan 5, 2024 | Lung Cancer |
The diagnostic, which requires only a simple urine test to read the results, could make lung cancer screening more accessible worldwide.
Read More